LAPIP — Laser-Assisted Peri-Implantitis Procedure Template

LAPIP (Laser Assisted Peri-Implantitis Protocol).

RMH: Medical history reviewed/updates
Vitals: BP/pulse; other vitals if indicated

Implant site: #Tooth number(s)
Pre-op probing depths: Pre-op probing depths
Bone loss noted: Bone loss noted

LAPIP support: Implant placement/restoration date, implant system/site, peri-implantitis diagnosis
Peri-implant disease documentation: Probing depths, BOP/suppuration, radiographic bone loss
Surface/graft details: Implant detoxification method, graft/biologic/membrane details

Consent: Consent/PARQ reviewed; signed/verbally obtained

Anesthesia: Anesthetic used
Carps: Carpules/amount

Procedure:
Nd:YAG laser used.
Diseased tissue removed from peri-implant pocket.
Implant surface detoxified.
Titanium curettes used.
Laser used to stimulate bone regeneration.
Bone graft placed.
Fibrin clot created.
Tissue compressed around implant.

Complications: None or describe.

Patient tolerance: Tolerance/response.

Post-op instructions: Instructions reviewed.
Soft diet for 2 weeks.
Avoid chewing on treated area.
Salt water rinses only.
Rx: Prescription or none

NV: Next visit

Documentation requirements

LAPIP is a non-CDT proprietary protocol billed under D6101 (and frequently D6103) with a laser-procedure narrative, so the chart note is doing two jobs at once: (1) documenting the procedure clinically for the medico-legal record, and (2) constructing the audit-defensible narrative the carrier needs to pay D6101 above the D6081 fee schedule. The note that survives carrier review documents the diagnosis, the regenerative intent, the laser parameters, and the post-op pathway. A defensible LAPIP chart note includes:

• Updated medical history and vitals — RMH reviewed, medications, allergies, ASA status, BP/pulse. Diabetes (especially poorly controlled HbA1c >7%), smoking, bisphosphonate / antiresorptive history, immunosuppression, and prior head/neck radiation are all recognized peri-implantitis risk factors and should be flagged as risk contributors when present (2023 EFP S3 guideline).
• Implant identification — implant site by tooth number and arch position, implant system / manufacturer / diameter / length when known, date of placement, date of restoration, and time in function. Time-in-function matters: the carrier and your future self both need to distinguish "early biologic complication" from "long-standing peri-implantitis."
• Peri-implantitis case definition support — explicit case-definition language tied to a recognized standard. Document: (a) BOP and/or suppuration on gentle probing (≤0.25 N), (b) radiographic crestal bone loss compared with a reference radiograph, with the loss exceeding first-year physiologic remodeling (commonly >2 mm beyond baseline), (c) probing depth at the affected site (typically ≥5–6 mm). The 2018 AAP / 2017 World Workshop case definition is the U.S. standard; the 2023 EFP S3 guideline is the international consensus.
• Pre-op probing depths — six-point probing at the affected implant; baseline probing depths if available from the restorative or maintenance record. Differentiate true pocket depth from soft-tissue thickness around a deep-collared implant.
• Bleeding on probing and suppuration — explicit BOP, exudate, edema, erythema, recession, and any soft-tissue defect (peri-implant fistula). Photograph the site when feasible.
• Radiographic interpretation — current periapical of the implant (D0220) compared against a baseline (typically the post-restoration radiograph). Quantify the bone loss in mm and describe defect morphology (circumferential / crater / infrabony / dehiscence). Cone-beam imaging (D0364–D0367) is helpful when buccal/lingual loss is suspected and is documented separately.
• Diagnosis — explicit "peri-implantitis at #[tooth]" with the case-definition support beside it. Avoid generic phrasing like "implant problem" or "loose implant"; the carrier needs the diagnosis on the record.
• Consent / PARQ — the regenerative outcome of LAPIP is not guaranteed; the patient must understand that the alternative pathways are (a) open-flap peri-implantitis surgery, (b) implant removal (D6100) and possible re-implantation, or (c) continued non-surgical management with progression risk. PARQ should specifically address the off-label / non-CDT nature of the laser protocol, the cost implications of carrier non-coverage, and the realistic prognosis (LAPIP success rates in the published case series are favorable but not universal).
• Anesthesia — anesthetic agent, concentration, carpule count, and supplemental anesthesia (intraosseous, intraligamentary) when used. Field-block infiltration is typical; mandibular sites may require IAN block.
• Laser parameters (Nd:YAG) — laser type and serial unit, wavelength (1064 nm for the PerioLase MVP-7), pulse energy, pulse duration, repetition rate, total energy delivered, and the number of passes. The defensible note states "PerioLase MVP-7 free-running pulsed Nd:YAG, 1064 nm; first pass for diseased epithelium ablation; second pass for fibrin clot formation; pulse duration and energy per manufacturer protocol." Setting-level detail matters when the carrier requests records.
• Implant surface decontamination method — the specific detoxification step is the heart of the LAPIP narrative. Describe the sequence: laser pass to remove granulation tissue and diseased pocket epithelium, mechanical debridement with titanium curettes / titanium-coated ultrasonic tips (titanium instruments only — stainless instruments scratch the implant surface and contaminate the titanium oxide layer), chemical detoxification when used (citric acid, tetracycline, EDTA, chlorhexidine, saline lavage), and the second laser pass.
• Bone graft / biologic materials — when grafting is performed (usually the case in a contained infrabony defect), document graft material (allograft, xenograft, alloplast — type, particle size, lot number), volume placed, and any membrane or biologic adjunct (PRF, PRGF, enamel matrix derivative, growth factors). This is the documentation that supports the D6103 (bone graft for repair of peri-implant defect) companion code.
• Fibrin clot / tissue compression — the LAPIP-specific closure step: second Nd:YAG pass set to coagulate and form a fibrin clot at the bone-implant interface; tissue compressed against the implant; no sutures (or minimal sutures) consistent with the non-flap protocol. This phrasing is what differentiates the chart note from a conventional open-flap surgical narrative.
• Occlusal adjustment — common at the LAPIP visit. Document any reduction of cuspal interferences or eccentric contacts on the implant prosthesis to off-load the healing site.
• Post-op instructions — soft diet 2 weeks, avoid chewing on the treated side, salt-water rinses only (no mechanical brushing of the surgical site for the early healing window), no flossing/interdental brushing at the site until released, no smoking. The LAPIP protocol's expected fibrin-clot maturation depends on undisturbed healing.
• Prescriptions — antimicrobial regimen when used (systemic amoxicillin or amoxicillin/metronidazole are common adjuncts in published peri-implantitis protocols; doxycycline is an alternative), analgesic recommendations, and chlorhexidine 0.12% rinse instructions when prescribed.
• Re-evaluation / maintenance plan — explicit timeline. Standard LAPIP follow-up: 1-week soft-tissue check, 4–6 week early re-evaluation, 3-month perio/peri-implant re-evaluation with probing and radiograph, then transition to a 3-month peri-implant maintenance interval (reported as D6080 or D4910 depending on the case mix). Photograph the site at re-evaluation visits.
• Operator signature — the dentist who performed the procedure; LAPIP is a doctor procedure, not a hygiene procedure, regardless of how a similar D6080 maintenance visit might be delegated.

Patterns to avoid in a LAPIP chart note: (a) silence on the case-definition support (BOP / bone loss vs baseline / probing depth) — the carrier has nothing to adjudicate; (b) wording like "deep cleaning around implant" or "implant prophy," which sounds like D6080 or D6081 and invites a downcode; (c) mixing LAPIP with conventional flap-surgery language — pick one narrative; (d) omitting the graft material specifics when D6103 is being claimed; (e) auto-populated default-normal soft-tissue findings that contradict the peri-implantitis diagnosis.

Common denial reasons

The most frequent reasons LAPIP claims (D6101 + D6103, sometimes D6081) are denied, downgraded, or recouped:

• Diagnosis not documented to the case-definition standard. The single most common denial pattern. The chart says "peri-implantitis" without the supporting findings — no BOP/suppuration line, no baseline-vs-current radiographic comparison, no probing depths. Carriers downgrade D6101 to D6081 (or zero-pay) when the diagnosis isn't supported by the data.
• Laser-specific charge not separately reimbursable. Most carriers explicitly do not reimburse a laser premium; the procedure must stand on the underlying CDT code. Claims that include a non-CDT "LAPIP" line item, or that bill an unlisted code (D6199) for the laser portion, are rejected with a "service not covered" or "no fee schedule" response.
• D6103 graft denial — graft material not documented. When the bone graft component is denied, it's usually because the chart note didn't describe graft material type, particle size, volume, or — for allografts/xenografts — the lot number / source. Carriers requesting records expect graft documentation specific to the defect.
• No baseline radiograph to compare bone loss. Peri-implantitis case definition requires bone loss relative to a reference. When the chart cites "bone loss" without a baseline, the carrier may downgrade to peri-implant mucositis (which doesn't qualify for surgical-level codes).
• Pre-authorization not obtained. D6101 + D6103 combined on the same implant frequently requires pre-auth on commercial PPO and Medicaid MCO plans. Submitting without pre-auth on a plan that requires it is an automatic denial; appeal usually succeeds with the pre-auth packet retroactively, but at the cost of weeks.
• Peri-implant mucositis miscoded as peri-implantitis. A chart with BOP but no radiographic bone loss documents peri-implant mucositis, which is treated with non-surgical hygiene and reported under D6081 — not D6101. Misuse of D6101 for mucositis is a recurring audit finding.
• Implant not in function long enough for peri-implantitis diagnosis. An implant with bone loss in the first year of function may be exhibiting first-year physiologic remodeling, not peri-implantitis. Carriers sometimes deny D6101 when time-in-function is short and bone loss is borderline.
• Frequency violation on the same implant. Repeating D6101 on the same implant within 12 months without documentation of disease recurrence triggers manual review and frequent denial.
• Same-day bundling with D6080 or D6081. D6101 is mutually exclusive on the same date with D6080 (maintenance) and D6081 (debridement). Billing two scaling-family codes on the same implant on the same day zeros out the lower-fee code.
• Procedure narrative reads like maintenance. If the chart says "implant cleaning" or "ultrasonic scaling around implant" without surgical / debridement / regenerative language, the carrier reads the case as D6080/D6081 even when D6101 was billed.
• Missing operator — D6101 is a doctor-performed procedure; chart notes documented under hygienist signature alone are flagged.
• Off-label / non-FDA-cleared laser claims. The PerioLase MVP-7 is FDA-cleared for the LAPIP protocol; using a different Nd:YAG or diode laser and billing the procedure as "LAPIP" is a documentation problem if the carrier requests details.
• Implant prognosis poor — case should have been D6100. When the records suggest the implant was not salvageable (mobility, fracture, complete loss of integration), carriers may deny D6101 + D6103 on medical-necessity grounds; the appropriate code was D6100 (implant removal).

Related templates